Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?

被引:361
作者
Saas, P
Walker, PR
Hahne, M
Quiquerez, AL
Schnuriger, V
Perrin, G
French, L
Van Meir, EG
deTribolet, N
Tschopp, J
Dietrich, PY
机构
[1] UNIV HOSP, LAB IMMUNOL TUMEURS, DIV ONCOL, CH-1211 GENEVA 14, SWITZERLAND
[2] UNIV LAUSANNE, INST BIOCHEM, CH-1066 EPALINGES, SWITZERLAND
[3] UNIV GENEVA, DIV DERMATOL, SCH MED, CH-1211 GENEVA 14, SWITZERLAND
[4] CHU VAUDOIS, LAB TUMOR BIOL & GENET, NEUROSURG SERV, CH-1011 LAUSANNE, SWITZERLAND
关键词
central nervous system; CD95; glioma; immune tolerance; apoptosis;
D O I
10.1172/JCI119273
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Astrocytomas are among the most common brain tumors that are usually fatal in their malignant form. They appear to progress without significant impedance from the immune system, despite the presence of intratumoral T cell infiltration. To date, this has been thought to be the result of T cell immunosuppression induced by astrocytoma-derived cytokines. Here, we propose that cell contact-mediated events also play a role, since we demonstrate the in vivo expression of Fas ligand (FasL/CD95L) by human astrocytoma and the efficient killing of Fas-bearing cells by astrocytoma lines in vitro and by tumor cells ex vivo. Functional Fast is expressed by human, mouse, and rat astrocytoma and hence may be a general feature of this nonlymphoid tumor. In the brain, astrocytoma cells can potentially deliver a death signal to Fas(+) cells which include infiltrating leukocytes and, paradoxically, astrocytoma cells themselves. The expression of Fast by astrocytoma cells may extend the processes that are postulated to occur in normal brain to maintain immune privilege, since we also show Fast expression by neurons. Overall, our findings suggest that Fast-induced apoptosis by astrocytoma cells may play a significant role in both immunosuppression and the regulation of tumor growth within the central nervous system.
引用
收藏
页码:1173 / 1178
页数:6
相关论文
共 35 条
  • [1] BARKER CF, 1977, ADV IMMUNOL, V25, P1
  • [2] A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION
    BELLGRAU, D
    GOLD, D
    SELAWRY, H
    MOORE, J
    FRANZUSOFF, A
    DUKE, RC
    [J]. NATURE, 1995, 377 (6550) : 630 - 632
  • [3] BODMER S, 1989, J IMMUNOL, V143, P3222
  • [4] BORDIER C, 1981, J BIOL CHEM, V256, P1604
  • [5] CERVICAL LYMPHATICS, THE BLOOD-BRAIN-BARRIER AND THE IMMUNOREACTIVITY OF THE BRAIN - A NEW VIEW
    CSERR, HF
    KNOPF, PM
    [J]. IMMUNOLOGY TODAY, 1992, 13 (12): : 507 - 512
  • [6] FABRY Z, 1995, J IMMUNOL, V155, P325
  • [7] NERVOUS-TISSUE AS AN IMMUNE COMPARTMENT - THE DIALECT OF THE IMMUNE-RESPONSE IN THE CNS
    FABRY, Z
    RAINE, CS
    HART, MN
    [J]. IMMUNOLOGY TODAY, 1994, 15 (05): : 218 - 224
  • [8] FONTANA A, 1982, J IMMUNOL, V129, P2413
  • [9] Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover
    French, LE
    Hahne, M
    Viard, I
    Radlgruber, G
    Zanone, R
    Becker, K
    Muller, C
    Tschopp, J
    [J]. JOURNAL OF CELL BIOLOGY, 1996, 133 (02) : 335 - 343
  • [10] Glass A, 1996, J IMMUNOL, V156, P3638